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Abstract
Background
Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs
currently treat infants aged 6 months and older. Here, we report findings from an infant
adverse event survey in 1–5 month olds who received azithromycin as part of a large com-
munity-randomized trial in Niger.
Methods and principal findings
Active surveillance of infants aged 1–5 months at the time of treatment was conducted in 30
randomly selected communities from within a large cluster randomized trial of biannual
mass azithromycin distribution compared to placebo to assess the potential impact on child
mortality. We compared the distribution of adverse events reported after treatment among
azithromycin-treated versus placebo-treated infants. From January 2015 to February 2018,
the caregivers of 1,712 infants were surveyed. Approximately one-third of caregivers
reported at least one adverse event (azithromycin: 29.6%, placebo: 34.3%, risk ratio [RR]
0.86, 95% confidence interval [CI] 0.68 to 1.10, P = 0.23). The most commonly reported
adverse events included diarrhea (azithromycin: 19.3%, placebo: 28.1%, RR 0.68, 95%
CI 0.49 to 0.96, P = 0.03), vomiting (azithromycin: 15.9%, placebo: 21.0%, RR 0.76, 95%
CI 0.56 to 1.02, P = 0.07), and skin rash (azithromycin: 12.3%, placebo: 13.6%, RR 0.90,
95% CI 0.59 to 1.37, P = 0.63). No cases of infantile hypertrophic pyloric stenosis were
reported.
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006950 November 12, 2018 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Oldenburg CE, Arzika AM, Maliki R, Kane
MS, Lebas E, Ray KJ, et al. (2018) Safety of
azithromycin in infants under six months of age in
Niger: A community randomized trial. PLoS Negl
Trop Dis 12(11): e0006950. https://doi.org/
10.1371/journal.pntd.0006950
Editor: Krithivasan Sankaranarayanan, University of
Oklahoma, UNITED STATES
Received: June 19, 2018
Accepted: October 27, 2018
Published: November 12, 2018
Copyright: © 2018 Oldenburg et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All data underlying
these analyses can be found at: https://dataverse.
harvard.edu/dataset.xhtml?persistentId=doi:10.
7910/DVN/MQYM5S.
Funding: The Bill and Melinda Gates Foundation
provided the funding for the trial (OPP1032340).
Pfizer Inc. (New York City) provided both the
azithromycin and the placebo oral suspensions.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Conclusions
Azithromycin given to infants aged 1–5 months appeared to be safe. Inclusion of younger
infants in larger azithromycin-based child mortality or trachoma control programs could be
considered if deemed effective.
Trial registration
ClinicalTrials.gov NCT02048007.
Author summary
Trachoma control programs currently treat all adults and children age 6 months and
older in communities endemic for trachoma. If shown to be safe, programs could consider
inclusion of younger children in mass treatment programs. Here, we evaluated adverse
events in infants aged 1–5 months who were participating in a placebo-controlled trial of
mass azithromycin for the reduction of child mortality in Niger. Overall, there was no dif-
ference in the frequency of adverse events among children treated with azithromycin
compared to placebo. Common adverse events in both arms included diarrhea, vomiting,
and skin rash. Azithromycin distribution to children between 1 and 5 months of age
appeared to be safe. Inclusion of younger children in azithromycin-based trachoma and
child mortality programs could be considered.
Introduction
Mass azithromycin distribution has been a core component of the World Health Organiza-
tion (WHO)’s trachoma control program, with over 700 million doses of azithromycin distrib-
uted to adults and children aged 6 months and older [1,2]. Mass azithromycin distribution
dramatically reduces the prevalence of the ocular strains of Chlamydia trachomatis that lead
to trachoma [3–7]. For most indications, azithromycin is approved by the Federal Drug
Administration (FDA) for use in children over 6 months of age, and programmatic treatment
of children under 6 months with azithromycin has been limited by lack of safety data [8].
Observational studies have documented an increase in infantile hypertrophic pyloric stenosis
(IHPS) following the use of macrolides in a child’s first month of life, with the greatest risk
associated with macrolide using during the first 14 days and with erythromycin in particular
[9–11]. These studies are limited by confounding by indication, as infants receiving macrolides
are generally sicker than their untreated peers and may have different indications for treatment
than those receiving other antibiotic classes. If shown to be safe, treatment of children less
than 6 months of age may be beneficial for trachoma control programs, as infants infected
with C. trachomatis have been shown to have a higher chlamydial load [4]. Higher chlamydial
loads have been shown to correlate with disease severity and children with higher loads may
be more likely to transmit infection [12].
Recently, the MORDOR (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résis-
tance) trial found a 14% reduction in all-cause child mortality following four rounds of bian-
nual mass azithromycin distribution to all children aged 1–59 months in Malawi, Niger, and
Tanzania compared to biannual placebo [13]. In MORDOR, the largest effects were seen in
children under 6 months of age, with nearly 1 in 4 deaths averted in azithromycin-treated
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communities. MORDOR enrolled children as young as 1 month (>28 days) of age. The pri-
mary MORDOR trial was a large simple trial [14], and as such was not designed to efficiently
evaluate adverse events other than mortality. Therefore, 30 communities were randomly
selected from each country for more intensive monitoring, including active adverse event
assessments. Here, we present adverse event data from children aged 1 to 5 months from the
Niger site of the trial, to establish the safety of provision of azithromycin to infants under 6
months of age.
Methods
Trial setting and eligibility
MORDOR was a community randomized, placebo-controlled trial conducted in Mangochi,
Malawi, Boboye and Loga, Niger, and Kilosa, Tanzania (ClinicalTrials.gov NCT02048007) that
compared biannual azithromycin distribution compared to biannual placebo distribution for
the prevention of childhood mortality. The current study is restricted to the Niger study site.
Methods for the trial have been previously reported [13]. Eligible communities had a popula-
tion between 200 and 2,000 inhabitants on the most recent national census. Children were eli-
gible for treatment if they were between 1 and 59 months of age and weighed at least 3,800
grams at the time of treatment. In each country, 30 of the randomized communities (15 per
arm) were randomly selected to participate in a morbidity sub-study. The morbidity commu-
nities included additional assessment of nutritional status as well as rectal swabs, nasal swabs,
nasopharyngeal swabs, and dried blood spot collection in a random sample of 50 children in
each community. The study intervention (biannual azithromycin or placebo) and census were
identical in morbidity and mortality communities. The infant adverse event study was con-
ducted in morbidity communities in Niger following each treatment round among all infants
aged 1 to 5 months per the most recent census.
Ethics statement
This study was approved by the Committee on Human Research at the University of Califor-
nia, San Francisco (10–01036) and the Institutional Review Board at the Niger Ministry of
Health (034/2017/CNERS). Due to low literacy levels in the study area, verbal informed con-
sent was obtained from village leaders and guardians of children. Caregiver assent for their
child to participate in the study was documented in the study mobile application. Both institu-
tional review boards approved the consent procedure. The study was conducted in accordance
with the Declaration of Helsinki.
Randomization and masking
Morbidity communities were randomized in a 1:1 fashion using R (R Foundation for Statisti-
cal Computing, Vienna, Austria). Participants, observers, investigators, and those performing
data cleaning were masked to treatment arm. The placebo was identical in appearance and in
packaging to the oral azithromycin suspension.
Census
A door-to-door census was conducted prior to each treatment round. All children aged 0–59
months and pregnant women were enumerated. Vital status was assessed (dead, alive,
unknown) at each follow-up census. Children who were aged between 1 and 5 months during
each census round in the morbidity communities were eligible for the infant adverse event
survey.
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Intervention
Every child aged 1–59 months at the most recent census was offered a single dose of directly
observed oral azithromycin or placebo (both provided by Pfizer, Inc, New York City). Each
child was given a volume of suspension equivalent to 20 mg/kg as estimated by height stick
approximation (per Niger’s trachoma guidelines) or by weight for those unable to stand. Treat-
ment was given after each examination round, with a treatment coverage target of 80%.
Adverse event survey
Following each treatment round, the caregivers of infants aged 1–5 months were interviewed
regarding adverse events since the last treatment, with a goal of interviewing caregivers within
2 weeks of treatment. A list of all infants aged 1–5 months based on the most recent census in
each morbidity community was generated, and we attempted to interview caregivers of all chil-
dren. Caregivers were asked if their child was treated as part of the study, and for those treated,
if the child had a health problem in the two-week period following treatment and if the child
was brought to a health clinic for treatment. Only caregivers of children who received the
study treatment were asked about health problems to estimate the incidence of health prob-
lems in treated children, as inclusion of untreated children could have biased estimates
towards the null. To estimate the intention-to-treat effect, all caregivers, regardless of whether
or not the mother reported that the child was treated, were asked if the child had any of the fol-
lowing symptoms since the last time the study team visited the child’s community: abdominal
pain, vomiting, nausea, diarrhea, dyspepsia, constipation, hemorrhoids, or skin rash.
Sample size considerations
The sample size for the morbidity communities was based off the primary morbidity outcome,
which was macrolide resistance in Streptococcus pneumoniae. We assumed 12% baseline resis-
tance (based on previous studies) and an ICC of approximately 0.051 (based on the Trachoma
Elimination Follow-up study [15]). We estimated that inclusion of 30 villages (15 per arm) and
10 samples per community would yield approximately 80% power to detect a difference in
prevalence of resistance of 18% (e.g., 12% versus 30%) assuming 80% carriage of S. pneumo-
niae. For the infant adverse event survey, the sample size was limited by the number of 1 to 5
month old children residing in the 30 communities during the study period.
Statistical analysis
Descriptive characteristics were calculated with medians and interquartile ranges (IQR) for con-
tinuous variables and proportions for categorical variables. Generalized linear models were used
to compare 1) if the child had a health issue within two weeks of treatment and 2) if the caregiver
sought medical care for the child within two weeks of treatment between the azithromycin and
placebo arms. Because the survey restricted questions related to health issues following treatment
to children who had received treatment, models were restricted only to children who received
treatment per caregiver report. A repeated measures model was used to assess whether there was
an overall difference in the distribution of adverse events in azithromycin- versus placebo-treated
infants, with a random effect for each child and study community. To estimate risk ratios for any
adverse event and each adverse event individually in azithromycin-treated infants compared to
placebo-treated infants, we used generalized linear models with a binomial distribution and log
link, with standard errors clustered by the community of residence of the infant (the unit of ran-
domization). All analyses were conducted in Stata version 14.2 (StataCorp, College Station, TX)
and R version 3.4.3 (The R Foundation for Statistical Computing).
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Results
Of 2,056 eligible infants, caregivers of 1,712 (83.3%) were interviewed between June 2015 and
February 2018 (Fig 1). The median time between each community’s treatment and the care-
giver survey was 34 days (IQR 21 to 61 days). There was no difference in the time between
treatment and caregiver survey between azithromycin and placebo-treated communities
(P = 0.78). Table 1 shows baseline characteristics of communities and infants included in this
study. Approximately half of the children were female (48.5%) and median age at the time of
the census was 2 months (IQR 1 to 4 months). Caregivers reported that 70.2% (N = 1,201) of
infants received study treatment, with no differences in treatment between arms (P = 0.22).
Fig 1. CONSORT diagram for the trial.
https://doi.org/10.1371/journal.pntd.0006950.g001
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Among infants for whom the caregiver reported receiving study treatment, there was no
difference in reports of any health problems in the two-week period following treatment
(34.1% azithromycin versus 40.3% placebo, P = 0.24, Table 2). Similarly, there was no differ-
ence in visiting a health clinic for a health problem among those who received treatment
(P = 0.27).
There was no difference in the overall distribution of adverse events in children between
the two study arms (P = 0.43, repeated measures model). Overall, caregivers of 32.7% of all
infants reported at least one adverse event (Table 3). The most commonly reported adverse
events in the period following treatment included diarrhea (25.2%), vomiting (19.3%), and
skin rash (13.1%). There was no difference overall in report of any adverse event (RR 0.86,
95% CI 0.68 to 1.10, P = 0.23). Infants in the azithromycin-treated arm had reduced risk of
diarrhea (RR 0.68, 95% CI 0.49 to 0.96, P = 0.03) and hemorrhoids (RR 0.27, 95% CI 0.08 to
0.87, P = 0.03). The distribution of all other adverse events was similar between treatment
arms. There were no reported cases of IHPS.
Discussion
Trachoma control programs currently only treat children aged 6 months and older, with youn-
ger children receiving topical tetracycline. The majority of FDA-approved indications for azi-
thromycin include children aged 6 months and older. Here, we were unable to find any
evidence of an increase in adverse events in a sample of infants receiving azithromycin versus
placebo as part of a community randomized trial. These results suggest that azithromycin
treatment may be safe in infants under 6 months of age, and expansion of indications for azi-
thromycin in public health programs such as trachoma control to include children under 6
months of age could be considered.
Previous evaluation of the safety of azithromycin in children under 6 months of age have
consisted of large epidemiologic studies or small randomized controlled trials of azithromycin
use among very low birth weight neonates for the prevention of bronchopulmonary dysplasia
[8–10,16–19]. Epidemiologic cohorts have shown no increase in risk of IHPS in children over
6 weeks of age compared to untreated children, but may be subject to confounding by indica-
tion. In the general population, the vast majority of IHPS cases are diagnosed during the first
12 weeks of life, with a sharp decline in incidence after the 5-6th week of life [20]. Population-
based estimates of IHPS in sub-Saharan Africa are rare, but IHPS is thought to be less common
in sub-Saharan Africa than in other regions, potentially due to differences in practices that
have been shown to increase risk, such as bottle and formula feeding [21–23]. Although no
Table 1. Characteristics by study arm.
Azithromycin Placebo
Caregiver interviews N = 571 N = 1,141
Female, N (%) 280 (49.7%) 542 (47.9%)
Age at survey, months (median, IQR) 2 (1 to 4) 3 (1 to 4)
Abbreviations: IQR, interquartile range
https://doi.org/10.1371/journal.pntd.0006950.t001
Table 2. Healthcare visits following treatment among infants aged 1–5 months receiving treatment (N = 1,201).
Azithromycin Placebo RR (95% CI) P-value
Any health problem 131 (34.1%) 329 (40.3%) 0.85 (0.64 to 1.12) 0.24
Had health problem and visited clinic 49 (12.8%) 137 (16.8%) 0.76 (0.47 to 1.23) 0.27
https://doi.org/10.1371/journal.pntd.0006950.t002
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cases of IHPS were reported, the present study was underpowered to assess IHPS, given its rar-
ity particularly among children over one month of age [9,20]. Projectile vomiting is the most
common symptom of IHPS [24], however the risk of vomiting in the present study was lower
in azithromycin-treated infants compared to placebo-treated infants, suggesting that azithro-
mycin did not lead to IHPS in this population. While future studies using azithromycin in chil-
dren under 12 weeks of age should remain vigilant in screening for IHPS, the results of this
study suggest that the risk of IHPS is likely rare in this population.
Trachoma control programs distribute azithromycin to children and adults aged 6 months
and older in communities with endemic trachoma. Although infants under 6 months are
thought to have lower infection rates than older children [25], earlier treatment of infants for
trachoma may reduce community prevalence of C. trachomatis as infants may have a higher
chlamydial load if infected [4]. Caregivers of infants under 6 months of age are given topical
tetracycline ointment with instructions to apply the ointment daily for 6 weeks, however com-
pletion of the regimen is generally thought to be poor [25–28]. The ability to expand azithro-
mycin distribution to children as young as one month of age could potentially contribute to
reductions in trachoma in endemic regions if treatment of children under 6 months of age
with azithromycin is shown to be effective for trachoma control.
A subgroup analysis of the MORDOR study demonstrated a nearly 25% reduction in mor-
tality among infants under 6 months of age compared to an overall decrease of 14%, generating
the hypothesis that the largest effects of azithromycin for prevention of child mortality may be
in the youngest age groups [13]. Previous studies have shown a significant decrease in child
mortality among children aged 6–59 months in the context of azithromycin distribution for
trachoma control [29–31]. Younger children are at higher risk of mortality compared to older
children [32]. The potential for benefit from a mortality-reducing intervention, such as azi-
thromycin, may be greater in this age group than in all children under the age of 5. In the par-
ent study, which included more than 300,000 person-years at risk, few adverse events were
reported, although active surveillance was not undertaken. The parent study was a large simple
trial designed specifically to evaluate the effect of azithromycin on mortality, which can be con-
sidered the most serious adverse event. However, this design was not efficient for evaluation of
other adverse events due to the sample size required for the study to be adequately powered for
the mortality outcome, given that mortality is a rare event. Active adverse event monitoring
was therefore only conducted in the smaller morbidity study, which included more intensive
monitoring of study participants.
Table 3. Adverse events following azithromycin treatment among infants aged 1–5 months in communities randomized to azithromycin or placebo (N = 1,712).
Azithromycin Placebo RR (95% CI) P-value
Any adverse event 169 (29.6%) 391 (34.3%) 0.86 (0.68 to 1.10) 0.23
Abdominal pain1 52 (9.1%) 116 (10.2%) 0.90 (0.45 to 1.77) 0.75
Vomiting1 91 (15.9%) 240 (21.0%) 0.76 (0.56 to 1.02) 0.07
Nausea1 28 (4.9%) 55 (4.8%) 1.02 (0.34 to 3.04) 0.98
Diarrhea1 110 (19.3%) 321 (28.1%) 0.68 (0.49 to 0.96) 0.03
Dyspepsia1 17 (3.0%) 20 (1.8%) 1.70 (0.25 to 11.45) 0.59
Constipation1 32 (5.6%) 66 (5.8%) 0.97 (0.42 to 2.23) 0.94
Hemorrhoids1 7 (1.2%) 52 (4.6%) 0.27 (0.08 to 0.87) 0.03
Skin rash1 70 (12.3%) 155 (13.6%) 0.90 (0.59 to 1.37) 0.63
1Assessed via caregiver report, overall P = 0.43
https://doi.org/10.1371/journal.pntd.0006950.t003
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The results of this study must be considered in the context of several limitations. MORDOR
did not enroll children under one month of age, and thus we cannot comment on the safety of
azithromycin in neonates. Active surveillance was conducted via caregiver report, which could
be subject to social desirability or recall biases. Due to inability to link study records to clinic
records, we did not attempt to validate caregiver responses against health post or hospital rec-
ords. Estimates may therefore be an over- or underestimate of the true burden of adverse
events. Although we planned to survey caregivers within two weeks of treatment, due to logis-
tical challenges the survey was often conducted several weeks following treatment. A longer
duration between treatment and the survey could increase the likelihood of misclassification.
However, due to the use of masked placebo, any misreporting is unlikely to be differential with
respect to study arm. In addition, a longer duration between treatment and the survey could
increase the number of events that occurred with decreased probability that they were related
to study treatment, which could bias results towards the null. However, there were no signifi-
cant differences in the effect of azithromycin versus placebo by timing of the survey on any
adverse event reporter in this study. Although we attempted to interview the caregiver of each
child, only 83% of eligible children’s caregivers were interviewed. Due to the placebo-masked
nature of the study, differential response by arm is unlikely, however it is possible that caregiv-
ers of children who died were less likely to be interviewed. The probability of mortality is very
low, and thus unlikely to substantially bias results. This study was conducted in one of three of
the MORDOR trial sites, in a region of the Sahel with very high child mortality and infection
rates. The results of this study may only be generalizable to other regions with similar distribu-
tions of childhood infection.
The results of MORDOR suggest there may be a large reduction in mortality in the 1 to 5
month age group with the use of azithromycin, but as a large simple trial, the trial was not
ideal for quantifying common adverse events. In this ancillary study, we were unable to find a
difference in adverse events in infants aged 1 to 5 months participating in a large community-
randomized trial of biannual mass azithromycin distribution for prevention of child mortality.
Currently, several guidelines indicate azithromycin for use in children over 6 months of age.
These results suggest that azithromycin could be considered in infants over 1 month of age,
and their inclusion in various public health programs using azithromycin may be appropriate.
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